News

Teva Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) answering the pharmaceutical’s New Drug Application (NDA) for SD-809 (deutetrabenazine) tablets, for the treatment of chorea associated with Huntington’s disease (HD), a condition reported by nearly 90 percent of all Huntington’s…

Groundbreaking research from the University of Copenhagen showed that healthy glial cells, transplanted into the brains of mice in a Huntington’s disease model, improved symptoms and prolonged the animals’ lives, demonstrating that glial cells actively contribute to disease processes — a finding with potentially far-reaching implications for the research into, and treatment…

Korean researchers have demonstrated for the first time that transplanting cells from a patient with Huntington’s disease (HD) into mice leads to the development of the pathology in the animal through the propagation of mutated huntingtin (HTT). The study “Human-to-mouse prion-like propagation of mutant huntingtin protein,” was published in…

A multi-institutional study led by a team of biomedical researchers in the lab of Hui-Chen Lu at Indiana University at Bloomington, Indiana, has discovered evidence indicating that the enzyme nicotinamide mononucleotide adenylyl transferase 2 (NMNAT2) may have protective qualities against debilitating effects of certain degenerative brain diseases called proteinopathies, that…

NEAT1 (Nuclear Enriched Abundant Transcript 1), a long non-coding RNA molecule, might be protecting neurons in Huntington’s disease (HD) a new study suggests.

During the 68th American Academy of Neurology (AAN) meeting in Vancouver, Teva Pharmaceutical Industries Ltd. presented new results from its Phase III First-HD clinical trial evaluating the efficacy, safety and tolerability of SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington’s disease (HD), a…

A collaboration between researchers at the University of Leicester, U.K., and the University of Maryland School of Medicine, Baltimore, may lead to a way of reversing some symptoms of neurogedenerative diseases, like Huntington’s, by blocking two specific enzymes of the kynurenine pathway. The findings, published in the Proceedings of the…

A protein, known for its role in the kidneys, has been identified by University of Louisville scientists as a key player in axonal branching –  a process by which nerve cells extend  processes to connect to other nerve cells. The discovery of the protein’s crucial role will shed light…

Scientists at the University of Guelph in Canada, have concluded in a recent study, that exercise can increase the use of the neurotransmitter glutamate in the brain, potentially lowering toxicity associated with excessive levels of the compound in neurodegenerative conditions such as Huntington’s disease. Glutamate is one of the…

A professor at Washington University in St. Louis, Missouri, has been awarded two grants from the National Institutes of Health (NIH) totaling over $4.5 million to study Huntington’s disease (HD) and the causes behind this devastating disease. The recipient of the grants is Rohit V. Pappu, the Edwin H. Murty Professor…